Indivior agrees to pay out $385M to end yearslong Suboxone litigation and accusations it prevented generic competition
Virginia-based Indivior will pay out $385 million to bring an end to litigation over accusations it prevented generic competition to its opioid addiction treatment Suboxone, halting a trial scheduled to begin on Oct. 30.
As part of the agreement with direct purchasers who were part of the multi-district litigation, Indivior will pay out the $385 million in November from its existing cash. The company will also take a charge of $228 million in the third quarter and exclude that from its adjusted earnings.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.